Abstract |
Rational chemotherapy of malignant melanoma could be developed by taking advantage of the presence of melanogenic enzymes in melanoma cells. 4-S-Cysteaminylphenol (4-S-CAP) has been evaluated for melanocytotoxicity and antimelanoma effect. Although 4-S-CAP is selectively toxic to pigmented melanoma cells, it is not potent enough when applied as a single agent. To increase the efficacy of 4-S-CAP, we synthesized 4-S-cysteaminylcatechol (4-S-CAC), an activated form of 4-S-CAP, and compared its biochemical properties and antimelanoma effects with those of the isomers 3-S-cysteaminylcatechol (3-S-CAC) and 2-S-cysteaminyl-hydroquinone (2-S-CAH). 4-S-CAC was found to be a better substrate for melanoma tyrosinase than was L-3,4-dihydroxyphenylalanine, the natural catecholic substrate. 3-S-CAC was a poor substrate, whereas 2-S-CAH was not a substrate. 4-S-CAC was the most cytotoxic to three lines of melanoma cells in vitro, followed by 2-S-CAH and 3-S-CAC. When applied i.p. for 9 days at a dose of 100 mg/kg, 4-S-CAC.HCl, increased by 46-52% the life span of C57BL/6 mice inoculated i.p. with B16 melanoma; this effect was comparable to that of a 50 mg/kg dose of 5-(3,3-dimethyltriazenyl)-1H-imidazole-4-carboxamide. 3-S-CAC was marginally effective, whereas 2-S-CAH was toxic to the host. This systemic toxicity of 2-S-CAH reflected its susceptibility to autoxidation. Growth of B16 melanoma cells inoculated s.c. was significantly inhibited by i.p. administration of 4-S-CAC.HCl (200 mg/kg) for 5 days (P < 0.05). These results suggest that 4-S-CAC is a potent antimelanoma agent, the effect of which is mostly mediated through tyrosinase oxidation.
|
Authors | S Inoue, K Hasegawa, S Ito, H Ozeki, F Solano, C Jiménez-Cervantes, K Wakamatsu, K Fujita |
Journal | Cancer research
(Cancer Res)
Vol. 55
Issue 12
Pg. 2603-7
(Jun 15 1995)
ISSN: 0008-5472 [Print] United States |
PMID | 7780975
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- 4-S-cysteaminylcatechol
- Antineoplastic Agents
- Membrane Glycoproteins
- Proteins
- Levodopa
- Cysteamine
- Oxidoreductases
- TYRP1 protein, human
- Tyrp1 protein, mouse
- tyrosinase-related protein-1
- Monophenol Monooxygenase
- 4-S-cysteaminylphenol
|
Topics |
- Animals
- Antineoplastic Agents
(pharmacology, therapeutic use)
- Biotransformation
- Cell Division
(drug effects)
- Cell Line
- Cell Survival
(drug effects)
- Cysteamine
(analogs & derivatives, metabolism, pharmacology, therapeutic use)
- Dose-Response Relationship, Drug
- Humans
- Kinetics
- Levodopa
(pharmacology)
- Melanoma
(metabolism, pathology)
- Melanoma, Experimental
(drug therapy, pathology)
- Membrane Glycoproteins
- Mice
- Mice, Inbred C57BL
- Mice, Inbred DBA
- Monophenol Monooxygenase
(metabolism)
- Oxidation-Reduction
- Oxidoreductases
- Proteins
(metabolism)
- Tumor Cells, Cultured
|